Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy
Objectives - The aim of this study was to describe the population pharmacokinetics of vancomycin during prolonged intermittent renal replacement therapy (PIRRT) in critically ill patients with acute kidney injury. - Methods - Critically ill patients prescribed vancomycin across two sites had blood s...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
International journal of antimicrobial agents
Year: 2018, Jahrgang: 52, Heft: 2, Pages: 151-157 |
| ISSN: | 1872-7913 |
| DOI: | 10.1016/j.ijantimicag.2018.03.001 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.ijantimicag.2018.03.001 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0924857918300724 
|
| Verfasserangaben: | Caleb JP Economou, Jan T. Kielstein, David Czock, Jiao Xie, Jonathan Field, Brent Richards, Mandy Tallott, Adam Visser, Christina Koenig, Carsten Hafer, Julius J Schmidt, Jeffrey Lipman, Jason A Roberts |
| Zusammenfassung: | Objectives - The aim of this study was to describe the population pharmacokinetics of vancomycin during prolonged intermittent renal replacement therapy (PIRRT) in critically ill patients with acute kidney injury. - Methods - Critically ill patients prescribed vancomycin across two sites had blood samples collected during one to three dosing intervals during which PIRRT was performed. Plasma samples were assayed with a validated immunoassay method. Population pharmacokinetic analysis and Monte Carlo simulations were performed using Pmetrics®. The target vancomycin exposures were the area under the concentration-time curve within a 24-h period (AUC0-24)/minimum inhibitory concentration (MIC) ratio of 400 for efficacy and AUC0-24 700 for toxicity. - Results - Eleven critically ill patients (seven male) were enrolled and contributed 192 plasma samples. The patient's mean ± standard deviation (SD) age, weight and body mass index (BMI) were 57 ± 13 years, 98 ± 43 kg and 31 ± 9 kg/m2, respectively. A two-compartment linear model adequately described the data. The mean ± SD population pharmacokinetic parameter estimates were PIRRT clearance (CL) 3.47 ± 1.99 L/h, non-PIRRT CL 2.15 ± 2.07 L/h, volume of distribution of the central compartment (Vc) 41.85 ± 24.33 L, distribution rate constant from central to peripheral compartment 5.97 ± 7.93 per h and from peripheral to central compartment 5.29 ± 6.65 per h. Assuming a MIC of 1 mg/L, vancomycin doses of 25 mg/kg per day are suggested to be efficacious, whilst minimising toxic, exposures. - Conclusions - This is the first population pharmacokinetic study of vancomycin in patients receiving PIRRT and we observed large pharmacokinetic variability. Empirically, weight-based doses that are appropriate for the duration of PIRRT, should be selected and supplemented with therapeutic drug monitoring. |
|---|---|
| Beschreibung: | Gesehen am 19.05.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1872-7913 |
| DOI: | 10.1016/j.ijantimicag.2018.03.001 |